NASDAQ · BYAH

Park Ha Biological Technology Co.., Ltd.

$0.38 -$0.03 (-6.64%) 1D Pre-market

Key Metrics

$2.58M
Market cap
P/E · TTM
$2.52M
Revenue · TTM
−$24.36M
Net income
EPS · TTM $-48.73
Dividend yield
Free cash flow −$2.97K
Beta · 1Y 1.53
EBITDA · TTM −$23.98M
Gross margin 94.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Feb 9 high, the share price fell 93%.

    Peak close $5.19 on Feb 9; trough close $0.38 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -93%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 9
    The stock moved -41.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 9
  • Jun 8
    The stock moved +150.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 8

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.58M
Enterprise value
Shares outstanding6.4M
52-wk range$0.17 – $8.81
Avg volume · 20D1.8M
Net cash
Book value / share$7.99
ExchangeNASDAQ
About Park Ha Biological Technology Co.., Ltd.
IPO dateDec 27, 2024
Employees40

Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.02
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 94.4%
Operating -953.9%
Net -965.0%
FCF -0.1%
ROE / ROIC -885.8% · -11,760.4%

Financial Health

Current ratio2.92
Quick ratio2.88
Debt / equity
Debt / EBITDA
Net cash
Working capital$3.62M

Cash Flow · TTM

Operating CF $85.85K
Capex −$88.83K
Free cash flow −$2.97K
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-17.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-04-30 · computed by TickerWolf from SEC filings